Organisation paid for research Program year 2024 Source: CMS Open Payments

Trinity Medical Group

Neither a doctor nor a teaching hospital

Research payments

$368,608

205 payments

Through program year 2024, Trinity Medical Group is reported as receiving $368,608 in research payments, across 205 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$9,943	10
2023	Research	$1,789	1
2022	Research	$21,842	9
2021	Research	$63,341	48
2020	Research	$103,159	53
2019	Research	$168,535	84

Breakdown

Who paid Research payments · program years 2019–2024

AbbVie, Inc. $343,574 168 payments
Jazz Pharmaceuticals Inc. $17,274 8 payments
GlaxoSmithKline, LLC. $5,500 1 payment
Sun Pharmaceutical Industries Inc. $1,059 15 payments
Novartis Pharmaceuticals Corporation $617 1 payment
Noven Pharmaceuticals, Inc. $338 7 payments
Daiichi Sankyo Inc. $246 5 payments

Studies the money was for Research payments · program years 2019–2024

M15-554 $101,205 42 payments
M13-545 $96,326 45 payments
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Na?ve Subjects with Moderately to Severely Active Rheumatoid Arthritis $40,556 12 payments
M15-572 $40,251 26 payments
M13-542 $17,295 19 payments
Emerge 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca $17,274 8 payments
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate $13,755 5 payments
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) $13,033 8 payments
M15-998 $9,000 2 payments
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) $8,355 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.